Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis

Last updated: April 18, 2019
Sponsor: University Hospital, Brest
Overall Status: Completed

Phase

N/A

Condition

Rheumatoid Arthritis

Joint Injuries

Arthritis And Arthritic Pain

Treatment

N/A

Clinical Study ID

NCT02885818
ABATACEPT AND B CELL
  • Ages 18-75
  • All Genders

Study Summary

Abatacept disrupts T-cell coactivation signals in rheumatoid arthritis (RA). Its potential effects on B cells are not well described. This study will assess the effects of abatacept therapy on the phenotype and function of peripheral blood B cells in patients with RA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • RA as defined by ACR/EULAR criteria

  • Clinical indication to start abatacept therapy

Exclusion

Exclusion Criteria:

  • Treatment by rituximab in the previous year

Study Design

Total Participants: 20
Study Start date:
October 01, 2014
Estimated Completion Date:
January 11, 2018

Connect with a study center

  • CHRU de Brest

    Brest, 29609
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.